...be no demerger of the research & development (R&D) division and it is an integral part of the business. He told CNBC-TV18 that Ranbaxy is well positioned to capitalize on opportunities in the ...
5 months ago
moneycontrol.com
Keep this video in the "Saved" list
Now, put vTap to work for you!
Let us keep you up to date with new videos related to:
...be no demerger of the research & development (R&D) division and it is an integral part of the business. He told CNBC-TV18 that Ranbaxy is well positioned to capitalize on opportunities in the ...
5 months ago
moneycontrol.com
Keep this video in the "Saved" list
Now, put vTap to work for you!
Let us keep you up to date with new videos related to:
... pipeline and geographical presence is attractive. Tamae told CNBC-TV18 that they will explore other options if the 20% open offer does not happen. He staetd that they will make an open offer for ...
5 months ago
moneycontrol.com
Keep this video in the "Saved" list
Now, put vTap to work for you!
Let us keep you up to date with new videos related to:
... of 35% in Ranbaxy Labs at Rs 737/sh, which will also be priced at Rs 737 per share, reports CNBC-TV18. Daiichi's stake buy in Ranbaxy will trigger an open offer. Ranbaxy will make a preferential ...
5 months ago
moneycontrol.com
Keep this video in the "Saved" list
Now, put vTap to work for you!
Let us keep you up to date with new videos related to:
CNBC-TV18 has learnt that Pfizer could be interested in Ranbaxy. There is no confirmation from Pfizer, but sources say that it has informed its bankers to approach institutional shareholders. A bid for Ranbaxy at this stage may look difficult especia...
5 months ago
moneycontrol.com
Keep this video in the "Saved" list
Now, put vTap to work for you!
Let us keep you up to date with new videos related to: